HER2 is highly expressed in pediatric diffuse midline gliomas (DMGs)/DIPGs harboring H3 mutations, as well as in K27M wild-type and G34R-mutant hemispheric gliomas, making it a potential broad therapeutic target [51]. This evidence concerns the gene ERBB2 and glioma.